1-11 of 11
Lukas Smolej, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Comorbidities and Concomitant Medications on Survival of Patients with Chronic Lymphocytic Leukemia: Analysis of an Unselected Patient Population from East Bohemia

Pavel Vodarek, MD, Denisa Zeberova, Martin Simkovic, MD PhD, Monika Motyckova, MD PhD, David Belada, MD PhD, Pavel Žák, MD PhD, Lukas Smolej, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5328.
https://doi.org/10.1182/blood.V130.Suppl_1.5328.5328
Published: 2017
Journal Articles

Single-Agent Ibrutinib Versus Real-World Treatments for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Adjusted Comparison of Resonate-2™ with Real-World Databases

Gilles Salles, MD PhD, Lukas Smolej, MD PhD, Emmanuel Bachy, Lucile Baseggio, MD, Hervé Besson, Ruben Hermans, Nollaig Healy, Jamie Garside, Wafae Iraqi, Joris Diels, Finlay MacDougall, Corinna Pick-Lauer, Martin Spacek, Renata Urbanova, Daniel Lysak, Evelyne Callet-Bauchu, Michael Doubek, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5342.
https://doi.org/10.1182/blood.V130.Suppl_1.5342.5342
Published: 2017
Journal Articles

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Heidi Mocikova, MD, PhD, Jana Markova, MD, Lubica Gaherova, MD, Lukas Smolej, MD, PhD, Assoc.Prof., Martin Simkovic, MD, Tomas Kozak, MD, PhD, Prof.
Journal: Blood
Blood (2015) 126 (23): 5298.
https://doi.org/10.1182/blood.V126.23.5298.5298
Published: 2015
Journal Articles

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Richard Greil, MD, Petra Obrtlikova, MD PhD, Lukas Smolej, MD PhD, Tomas Kozak, MDPhD, Michael Steurer, MD, Johannes Andel, MD, Josef Thaler, MD, Eva Mikuskova, MD, Liana Gercheva, MD, Thomas Nösslinger, MD, Miriam Ladicka, MD, Michael Girschikofsky, MD, MikulᚠHrubiško, MD PhD, Prof., Ulrich Jäger, MD, Michael A. Fridrik, MD, Martin Pecherstorfer, MD, Eva Kralikova, MD, Cristina Burcoveanu, MD, Stefcho Goranov, MD, Jana Jurkovikova, MD, Andreas L. Petzer, MD, Georgi G. Mihaylov, MD PhD, Julian Raynov, MD, Horst Oexle, MD, August Zabernigg, MD, Emilia Flochova, MD PhD, Stanislav Palasthy, MD, Thomas Melchardt, MD, Jiri Mayer, MD, Alexander Egle, MD
Journal: Blood
Blood (2014) 124 (21): 20.
https://doi.org/10.1182/blood.V124.21.20.20
Published: 2014
Journal Articles

Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life

Michael Doubek, Yvona Brychtova, MD, PhD, Anna Panovska, MD, Jakub Trizuljak, MD, Ludmila Sebejova, Olga Stehlikova, MSc., Jana Chovancova, DVM, Jitka Malcikova, PhD, Jana Smardova, MD, PhD, Karla Plevova, MSc., Pavlina Volfova, MSc., Martin Trbusek, PhD, Marek Mraz, MD, PhD, Denisa Majercakova, MD, Petra Obrtlikova, MD, Josef Karban, MD, Lukas Smolej, MD, PhD, Michaela Lindtnerova, MD, Alexandra Oltova, MD, Eva Jelinkova, MSc., Sarka Pospisilova, Jiri Mayer, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2877.
https://doi.org/10.1182/blood.V122.21.2877.2877
Published: 2013
Journal Articles

Rituximab and High-Dose Dexamethasone (R-dex) Is Effective In The Treatment Of Relapsed/Refractory Chronic Lymphocytic Leukemia

Martin Simkovic, M.D., David Belada, M.D., Ph.D., Monika Motyckova, M.D., Lukas Smolej, MD, PhD, Pavel Zak, Assoc. Prof., MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4184.
https://doi.org/10.1182/blood.V122.21.4184.4184
Published: 2013
Journal Articles

A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study

Carol Moreno, MD, Marco Montillo, MD, Panayiotidis Panayiotis, MD, Adrian Bloor, PhD, FRCP, FRCPath, Jehan Dupuis, MD, Anna Schuh, MD, PhD, Stefan Norin, MD, Christian H Geisler, Peter Hillmen, MB ChB, PhD, Michael Doubek, Prof., Petra Obrtlikova, MD, Luca Laurenti, MD, Stephan Stilgenbauer, MD, Lukas Smolej, MD, PhD, Paolo Ghia, MD, PhD, Florence Cymbalista, MD, PhD, Ulrich Jaeger, Niki Stavroyianni, Patrick Carrington, MD, Hamadi Zouabi, MD, Veronique Leblond, MD, Juan Carlos Gomez, MD, Roberto Marasca, MD, Gerardo Musuraca, MD, PHD, Luigi Rigacci, MD, Lucia Farina, Rossella Paolini, Sarka Pospisilova, Prof., Eva Kimby, MD, Colm Bradley, Emili Montserrat, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1645.
https://doi.org/10.1182/blood.V122.21.1645.1645
Published: 2013
Journal Articles

Successful Treatment with Imatinib Mesylate Significantly Decreases Plasma Levels of Vascular Endothelial Growth Factor (VEGF) and Soluble Endoglin (sCD105) but Not Basic Fibroblast Growth Factor (bFGF) or Angiopoietin-2 (Ang-2) in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase

Lukas Smolej, MD, PhD, Ctirad Andrys, M.S., Ph.D., Jaroslava Voglova, M.D., Petra Belohlavkova, M.D., Jana Rabasova, M.S., Martin Beranek, PharmDr. Ph.D., Jaroslav Maly, M.D., Ph.D.
Journal: Blood
Blood (2008) 112 (11): 4252.
https://doi.org/10.1182/blood.V112.11.4252.4252
Published: 2008
Journal Articles

Angiopoietin-2 mRNA Expression Is Elevated in Chronic Lymphocytic Leukemia Patients with Poor Prognostic Features

Filip Vrbacky, MSc., Lukas Smolej, MD, PhD, Vladimira Vroblova, MSc., Sona Pekova, MD, PhD, Monika Hrudkova, MD, Miroslav Pecka, Jaroslav Maly, M.D., Ph.D.
Journal: Blood
Blood (2008) 112 (11): 4182.
https://doi.org/10.1182/blood.V112.11.4182.4182
Published: 2008
Journal Articles

Circulating Angiogenic Cytokines in Chronic Lymphocytic Leukemia: Relationship to Modern Prognostic Factors and Effect of Fludarabine-Based Treatment

Lukas Smolej, MD, PhD, Ctirad Andrys, M.S., Ph.D., Sona Pekova, M.D., PhD., Lenka Kucerova, M.S., Monika Hrudkova, M.D., David Belada, M.D., Ph.D., Jaroslav Maly, M.D., Ph.D.
Journal: Blood
Blood (2008) 112 (11): 4186.
https://doi.org/10.1182/blood.V112.11.4186.4186
Published: 2008
Journal Articles

Delta Ex6, the Novel Transactivation-Defective Splicing Variant of p53 Gene, Is Differentially Expressed in Patients with Chronic Lymphocytic Leukemia and Confers Accented Proliferative Phenotype in Vitro

Sona Pekova, M.D., PhD., Radek Cmejla, PhD, Tomas Kozak, MD, PhD, Lukas Smolej, MD, PhD, Martin Spacek, MD., Miroslav Prucha, MD., PhD., Ondrej Hrusak
Journal: Blood
Blood (2008) 112 (11): 3795.
https://doi.org/10.1182/blood.V112.11.3795.3795
Published: 2008